Lilly Wollman
Lilly is the co-founder and CEO of Synteny, a startup harnessing the adaptive immune system and artificial intelligence to engineer a
new generation of diagnostics, therapeutics and vaccines . Previously, Lilly was co-head of the Growth Equity platform for
Generation Investment Management, where she was responsible for the firm’s investments in sustainable technology companies (climate change and healthcare solutions).
After a 20-year track record in finance and investing, Lilly pursued a graduate degree in Computational Biology from the University of Cambridge
and was awarded the MPhil in Computational Biology (with distinction) in the fall of 2021.
At Cambridge, she worked as a research intern in the CRUK Early Detection Programme and completed her masters thesis
focused on generative models of TCR repertoires as part of the Accelerate Programme for Scientific Discovery.